Group 1: AMD - The MI350 series is expected to drive revenue growth in the second half of 2025, with management guiding a median revenue of $8.7 billion for Q3 2025, exceeding previous expectations [1][2] - Q2 2025 revenue reached $7.7 billion with a Non-GAAP gross margin of 43.3%, both surpassing forecasts [1] - The target price for AMD has been raised to $196, reflecting a potential upside of 12.4% based on a 35x P/E ratio for 2026 [2] Group 2: Property Trust - The property trust reported a slight revenue decline of 2.0% year-on-year to HKD 854.5 million for the first half of 2025, with net property income down 3.2% to HKD 612.6 million [3][7] - Distributable income and distribution per unit (DPU) increased by 2.1% and 1.0% year-on-year, respectively, aligning with expectations [3] - The average interest cost decreased significantly to 3.5%, down 60 basis points year-on-year, which is expected to support further increases in DPU [3] Group 3: Internet Industry - Tencent's domestic revenue decreased by 12% year-on-year, while overseas revenue showed a positive growth of 5% [8][9] - New game launches are expected to mitigate the impact of high revenue bases in the second half of the year, with an estimated annual game revenue growth of 12% [9] - NetEase's domestic revenue grew by 5%, driven by new game contributions, indicating a stable performance in the mobile gaming sector [8][9]

Report on the Investment Rating of the Hong Kong Real Estate Industry - The report maintains a "Buy" rating for The Link Real Estate Investment Trust (778 HK) and provides ratings for other companies in the Hong Kong real estate, mainland real estate, and property service sectors, including "Buy" and "Neutral" ratings [1][5] Core Viewpoints of the Report - The performance of The Link Real Estate Investment Trust in the first half of 2025 was stable, with the distribution per unit (DPU) in line with expectations. The Hong Kong retail portfolio remained resilient, and the occupancy rate was maintained at a high level. The decrease in interest expenses in the first half of the year offset the decline in revenue, and the dividend yield was over 7%. The report maintains a "Buy" rating with an unchanged target price of HK$5.86 [1] Summary of Relevant Content Performance in the First Half of 2025 - Revenue decreased slightly by 2.0% year-on-year to HK$854.5 million (HK$871.8 million in the first half of 2024). Net property income decreased by 3.2% to HK$612.6 million (HK$633.1 million in the first half of 2024). The distributable income and DPU increased by 2.1%/1.0% year-on-year to HK$377.1 million/18.41 HK cents, approximately 48.8% of the full-year forecast DPU of 37.71 HK cents [1] Retail Portfolio and Occupancy Rate - With the completion of the asset enhancement project of +WOO, the occupancy rate increased by 0.9 percentage points year-on-year to a high level of 95.0% (94.1% in the first half of 2024). 11 out of 17 malls had an occupancy rate of over 96%. The asset enhancement plan for The Metropolis Plaza was postponed, and the company planned to re-let the previously vacated areas. It was expected that the overall occupancy rate would further improve in the second half of the year, driving up rents. As of the end of June 2025, approximately 72% of the tenant portfolio was composed of daily necessities and essential services (by area and rent). The company planned to optimize the tenant portfolio and expected the overall rent of the malls to remain stable in the second half of the year [1] Interest Expenses - Due to the significant decline in HIBOR starting in May 2025, the overall average interest cost in the first half of 2025 was 3.5%, a year-on-year decrease of 60 basis points. The actual borrowing cost excluding the fair value change of derivative financial instruments decreased by 12.6% year-on-year to HK$173.3 million (HK$198.1 million in the first half of 2024). Approximately 50% of the company's floating-rate liabilities would continue to benefit from the decline in HIBOR in the second half of the year, saving more interest expenses to support the increase in DPU [1] Ratings and Target Prices of Other Companies - The report provides ratings and target prices for other companies in the Hong Kong real estate, mainland real estate, and property service sectors, including "Buy" and "Neutral" ratings, and calculates the potential upside for each company [5]

Investment Rating - The report assigns a "Buy" rating to several companies in the automotive sector, including BYD (1211 HK), XPeng Motors (9868 HK), and Geely Automobile (175 HK) [8]. Core Insights - The report highlights that the new energy vehicle market maintained a year-on-year growth in July, despite a slowdown in delivery growth due to the traditional off-season for passenger car sales [2][4]. - The overall delivery volume for new energy vehicles in July showed a year-on-year increase of 11.2% but a month-on-month decrease of 6.2% [6]. - The report anticipates an improvement in overall sales in August as the traditional peak sales season approaches [4]. Summary by Relevant Sections Company Performance - BYD delivered 341,030 vehicles in July, a slight year-on-year increase of 0.1% but a month-on-month decrease of 9.7% [6]. - Li Auto delivered 30,731 vehicles in July, reflecting a significant year-on-year decrease of 39.7% and a month-on-month decrease of 15.3% [6]. - XPeng Motors achieved a record delivery of 36,717 vehicles in July, marking a year-on-year increase of 229.4% and a month-on-month increase of 6.1% [6]. - NIO delivered 21,017 vehicles in July, with a year-on-year increase of 2.5% but a month-on-month decrease of 15.7% [4]. - Leap Motor delivered 50,129 vehicles in July, showing a year-on-year increase of 127% and a month-on-month increase of 4% [4]. Market Trends - The report notes that the penetration rate of new energy vehicles has remained above 50% for four consecutive months, indicating a strong market presence [2]. - The report expects that the upcoming launch of new models from various manufacturers will enhance market supply and drive sales during the peak season [4]. Future Outlook - Analysts are optimistic about the performance of BYD, XPeng Motors, and Geely following their new model launches and strategic initiatives [4].

Group 1: TAL Education (好未来教育) - The K12 education training business is performing steadily with a revenue of $580 million for Q1 FY2026, representing a 39% year-over-year increase. Adjusted operating profit reached $25 million, exceeding expectations [1] - The strong demand for small class tutoring and increased enrollment due to the expansion of teaching points are driving revenue growth. Sales of learning machines also showed healthy year-over-year growth, supported by the launch of new products [1] - For Q2 FY2026, the overall revenue growth is expected to be around 30%, maintaining the full-year revenue growth forecast at 28% with an adjusted operating profit margin projected to exceed 7%, doubling from FY2025 [1][2] Group 2: NIO Inc. (蔚来汽车) - The pricing strategy for the L90 model is aggressive, with the starting price set at RMB 265,800, which is lower than the previously announced pre-sale price. This pricing is expected to boost sales significantly [3] - The successful launch of the L90 model is anticipated to lead to stable monthly sales exceeding the market expectation of 5,000 units, paving the way for the upcoming L80 model [3][4] - Despite a 50% rebound from its low, NIO's 2025 price-to-sales ratio remains at 0.85, which is lower than its peers, indicating potential for continued stock price recovery [4]

Investment Rating - The report maintains a "Buy" rating for several companies in the biotechnology sector, including Legend Biotech (LEGN US), and others like 3SBio (1530 HK), Innovent Biologics (1801 HK), and more, indicating a positive outlook for these stocks [7]. Core Insights - The upcoming centralized procurement of biosimilars in mainland China is expected to impact multiple major products, with the first round of information collection already initiated [2]. - The report emphasizes that the impact of this procurement on company performance and product sales will likely be felt starting in 2026, as the process is expected to take longer due to the novelty of biosimilar procurement in China [2]. - Companies such as China Biologic Products, Innovent Biologics, and Hengrui Medicine are highlighted as key players with multiple products involved in the procurement process, warranting close attention to pricing and allocation results [2][3]. - The report suggests that the impact on innovative drugs will be limited, as the products involved in the procurement are off-patent and already have competing biosimilars [2]. Summary by Sections Section: Centralized Procurement - The centralized procurement for biosimilars is officially starting, with a focus on eight monoclonal antibody products [2]. - The information collection phase is expected to last 1-2 months, with a longer timeline anticipated for rule formulation and final product inclusion [2]. Section: Company Focus - Key companies to watch include China Biologic Products, Innovent Biologics, and Hengrui Medicine, with respective products in the procurement process [2]. - The report recommends monitoring the pricing and allocation outcomes closely for these companies [2]. Section: Innovative Drugs - The report indicates that the eight monoclonal antibodies involved in the procurement are already off-patent and have existing biosimilars, suggesting limited impact on innovative drugs still under patent [2]. - Continuous attention is advised for the upcoming national medical insurance negotiations and the establishment of commercial insurance innovative drug directories [2].

Investment Rating - The report assigns a "Buy" rating to TAL Education (TAL US) with a target price of $13.30, indicating a potential upside of 21.6% from the current closing price of $10.94 [1][13]. Core Insights - The K12 education training business is showing robust performance, driven by strong demand for quality education services and sales of learning devices [2][6]. - The financial outlook is positive, with projected revenue growth of 46.2% in 2024, 51.0% in 2025, and a steady decline to 13.2% by 2028 [3][14]. - The company is expected to maintain a strong growth trajectory in its learning services, with an estimated growth rate exceeding 30% [6][7]. Financial Overview - Revenue projections for TAL Education are as follows: $1,490 million in 2024, $2,250 million in 2025, $2,881 million in 2026, $3,422 million in 2027, and $3,873 million in 2028, reflecting a consistent upward trend [3][14]. - Net profit is expected to rise from $85 million in 2025 to $512 million by 2028, with significant growth rates in the initial years [3][14]. - The report highlights a Non-GAAP net profit of $150 million in 2025, increasing to $296 million in 2026, and $436 million in 2027 [3][14]. Performance Metrics - The report indicates a projected operating profit margin of over 7% for the fiscal year 2026, doubling from the previous year [6][7]. - The company’s earnings per share (EPS) are forecasted to grow from $0.14 in 2025 to $0.83 by 2028, demonstrating strong profitability potential [3][14]. - The price-to-earnings (P/E) ratio is expected to decrease from 78.2 in 2024 to 13.1 by 2028, indicating improving valuation as earnings grow [3][14]. Market Position - TAL Education is positioned favorably within the K12 education sector, with a strong market share in learning devices, achieving nearly 28% market share in sales [6][7]. - The company is expanding its product offerings, including AI learning devices aimed at enhancing educational experiences [6][7].

Investment Rating - The report maintains a "Buy" rating for NIO Inc. (9866 HK) [6][7]. Core Views - The pricing strategy for the new L90 model is aggressive, with the top configuration priced under 300,000 RMB, which is expected to significantly boost sales [1]. - The successful launch of the L90 is anticipated to pave the way for the upcoming L80 model, aiding NIO in reversing its sales trajectory [1]. - The report highlights that despite a 50% rebound from lower price levels, NIO's 2025 price-to-sales ratio remains at 0.85 times, which is lower than peers valued at 1-2 times, indicating potential for further price recovery [1]. Summary by Relevant Sections Pricing Strategy - The L90 model's starting price is set at 265,800 RMB for the Pro version, with Max and Ultra versions priced at 279,800 RMB and 299,800 RMB respectively. The seven-seat variant starts at 271,800 RMB [1]. - The Battery as a Service (BaaS) pricing starts at 179,800 RMB for the Pro version, with Max and Ultra versions priced at 193,800 RMB and 213,800 RMB respectively [1][2]. Product Features - All versions of the L90 come standard with an 85 kWh battery, L2 level intelligent driving assistance, and Orin-X chip [1]. - The Ultra version features dual-motor all-wheel drive, a 0-100 km/h acceleration time of 4.7 seconds, and unique seating configurations for enhanced comfort [2]. Sales Expectations - The report anticipates that monthly sales will exceed the market expectation of 5,000 units due to the favorable pricing and product features [1]. - The management's commitment to aggressive pricing reflects a strategic move to regain market share and improve sales performance [1].

Overview - The report highlights the synergy between the "anti-involution" policy and domestic demand policies, which is expected to drive the Hong Kong stock market to new highs in 2025 [2][5] - The "anti-involution" policy is being implemented across multiple industries, likely curbing price wars and boosting corporate profit expectations [2][5] - Demand-side policies, such as infrastructure projects and childcare subsidies, are providing positive support for market sentiment [2][5] Macro Strategy - The liquidity environment remains loose, but there are warnings about the potential for a temporary strengthening of the US dollar [2][3] - The Federal Reserve's interest rate cuts may be delayed until the fourth quarter of 2025 due to resilient economic indicators in the US [2][3] - Despite the crowded short positions on the dollar, the current liquidity in the Hong Kong market is ample, with reasonable valuation levels providing an ideal allocation window for investors [2][3] Industry Allocation Strategy - The report maintains a "high elasticity" and "high dividend" barbell strategy for industry allocation [4][6] - The internet and AI hard technology sectors are expected to benefit from a slowdown in subsidy wars, with corporate profits likely to be revised upwards [6] - The biopharmaceutical sector is supported by ample funding from overseas pharmaceutical giants and a rich pipeline of innovative drugs in mainland China [6] - Traditional industries and emerging sectors like photovoltaics and lithium batteries are expected to benefit from improved industry competition dynamics due to the "anti-involution" policy [6] - High-dividend sectors such as banking and insurance are recommended as stable income sources during market volatility [6] Company Highlights - **China Ping An (2318HK)**: Expected to benefit from a favorable stock market environment, with an attractive valuation and a target price of HKD 73.00, representing a potential upside of 35.3% [7][9] - **Link REIT (823HK)**: Anticipated to maintain stable dividends with a target price of HKD 47.70, reflecting an 8.7% potential upside, supported by a favorable consumption environment [15][17] - **OmniVision Technologies (603501CH)**: Positioned to benefit from domestic semiconductor supply chain localization and rising automotive demand, with a target price of RMB 180.00, indicating a potential upside of 48.4% [20][22] - **Alibaba (BABAUS/9988HK)**: Expected to see valuation adjustments driven by AI and cloud business leadership, with a target price of USD 165, representing a potential upside of 40.6% [28][30] - **Xpeng Motors (9868HK)**: Projected to achieve breakeven due to strong new car cycles, with a target price of HKD 134.69, indicating an 88.1% potential upside [34][36] - **Zymeworks (6996HK)**: Highlighted for its promising drug pipeline and potential for significant revenue growth, with a target price of HKD 6.60, representing a 14.2% upside [41][43] - **Anta Sports (2020HK)**: Expected to drive high-quality growth through a multi-brand strategy, with a target price of HKD 110.20, indicating a potential upside of 22.4% [45][47]

Global Macro - The Federal Reserve decided to maintain the federal funds rate target range at 4.25%-4.5%, marking the fifth consecutive meeting without a rate cut, aligning with market expectations [2] - The meeting saw two dissenting votes from Board members Bowman and Waller, who favored an immediate 25 basis point cut, marking the first time since 1993 that two members voted against the consensus [2] - The Fed's statement removed previous language indicating reduced uncertainty, emphasizing that economic uncertainty remains high, reflecting a more hawkish stance [2] - Powell's comments indicated that the Fed is committed to its independence despite external pressures, particularly from former President Trump, and that the impact of tariffs on the economy is still uncertain [2][4] Labor Market and Rate Cut Expectations - Powell dismissed the need for preemptive rate cuts to counter potential labor market downturns, asserting that the labor market remains robust [3] - The dissenting members expressed concerns about labor market vulnerabilities, but Powell maintained that current economic performance does not warrant a premature rate cut [3] - Following the meeting, the probability of a rate cut in September dropped from approximately 65% to around 45%, with expectations for one to two cuts by the end of 2025 [5] Economic Indicators - The U.S. GDP showed a significant rebound in Q2 2025, indicating a recovery in economic activity [9] - The labor market remains strong, with non-farm payrolls increasing by 147,000 and an unemployment rate of 4.1% [11] - Inflation indicators suggest a rising trend in commodity prices, with core PPI and CPI showing upward movements [15][16]

Investment Rating - The report assigns a "Buy" rating for Budweiser APAC (1876 HK) [4][15]. Core Insights - The company experienced a 5.6% year-on-year decline in revenue for the first half of 2025, with a total revenue of $3.14 billion. The EBITDA also fell by 8.0% to $980 million, reflecting challenges in sales and a slow premiumization process [2][8]. - The report anticipates a marginal recovery in the second half of 2025, particularly in the Chinese market, as the company focuses on expanding non-immediate consumption channels [2][7]. - The target price for Budweiser APAC is set at HKD 10.15, indicating a potential upside of 15.7% from the current price of HKD 8.77 [1][12]. Financial Overview - Revenue projections for Budweiser APAC show a decline from $6.856 billion in 2023 to $6.176 billion in 2025, with a slight recovery expected in subsequent years [3][13]. - The net profit is forecasted to decrease from $852 million in 2023 to $741 million in 2025, with a gradual increase to $871 million by 2027 [3][13]. - The EBITDA margin is expected to decline from 29.5% in 2023 to 29.2% in 2025, with a slight recovery anticipated thereafter [14]. Market Performance - The stock has shown a year-to-date increase of 17.09%, with a 52-week high of HKD 10.82 and a low of HKD 6.94 [6][12]. - The average daily trading volume is reported at 21.61 million shares, indicating active market participation [6].